Form 4: Johnson & Johnson Executive Jennifer Taubert Reports Stock Option and Restricted Share Unit Awards

EVP Jennifer Taubert reports the acquisition of stock options and restricted share units in Johnson & Johnson under the company's Long-Term Incentive Plan.

Summary

• Jennifer Taubert, an Executive Vice President at Johnson & Johnson, filed a Form 4 on February 19, 2025, reporting transactions related to the company's stock.
• On February 15, 2025, Taubert was awarded 89,781 employee stock options with an exercise price of $156.15, vesting in three equal annual installments starting one year from the grant date and expiring on 02/15/2035.
• Additionally, Taubert received 5,539 restricted share units (RSUs) that also vest in three equal annual installments beginning on the first anniversary of the grant date and convert into common stock on a one-for-one basis upon vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The grant of stock options and RSUs aligns executive compensation with the long-term performance of Johnson & Johnson.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.

Industry Context

Stock option and RSU grants are common practices in executive compensation packages within the pharmaceutical industry to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among large pharmaceutical companies like Pfizer (PFE), Merck (MRK), and AbbVie (ABBV).
• The vesting schedules and grant sizes are generally aligned with industry norms for executives at similar levels within these organizations.
• These grants are designed to incentivize long-term performance and retention, similar to practices observed across the sector.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive incentive for executive performance.
• Employees may see this as a standard practice for executive compensation within the company.
• The grants do not have a direct impact on customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted share units, JNJ, Johnson & Johnson, executive compensation, Jennifer Taubert